alanine has been researched along with Thrombopenia in 9 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 9.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "Thrombocytopenic episodes occurring in 18,845 patients treated with the GPIIb/IIIa inhibitors xemilofiban and orbofiban ("fibans") were analyzed by a blinded review panel and 73 patients were classified as having "possible fiban-induced thrombocytopenia"." | 9.10 | Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. ( Aster, RH; Brassard, JA; Cannon, CP; Cooper, RA; Curtis, BR; Ehardt, M; Ferguson, J; Komocsar, W; Kupfer, S; Maurath, C; Swabb, E, 2002) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 5.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "Thrombocytopenic episodes occurring in 18,845 patients treated with the GPIIb/IIIa inhibitors xemilofiban and orbofiban ("fibans") were analyzed by a blinded review panel and 73 patients were classified as having "possible fiban-induced thrombocytopenia"." | 5.10 | Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. ( Aster, RH; Brassard, JA; Cannon, CP; Cooper, RA; Curtis, BR; Ehardt, M; Ferguson, J; Komocsar, W; Kupfer, S; Maurath, C; Swabb, E, 2002) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| "To assess the effect on metastasis, XV454 was administered intravenous or orally 10 minutes and 3 hrs before tumor cell injection, respectively." | 1.32 | Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. ( Amaya, M; Amirkhosravi, A; Blaydes, S; Desai, H; Francis, JL; Meyer, T; Mousa, SA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yalçın, N | 1 |
| Demirkan, K | 1 |
| Abrams, CS | 1 |
| Cines, DB | 1 |
| Brassard, JA | 1 |
| Curtis, BR | 1 |
| Cooper, RA | 1 |
| Ferguson, J | 1 |
| Komocsar, W | 1 |
| Ehardt, M | 1 |
| Kupfer, S | 1 |
| Maurath, C | 1 |
| Swabb, E | 1 |
| Cannon, CP | 3 |
| Aster, RH | 2 |
| Amirkhosravi, A | 1 |
| Mousa, SA | 1 |
| Amaya, M | 1 |
| Blaydes, S | 1 |
| Desai, H | 1 |
| Meyer, T | 1 |
| Francis, JL | 1 |
| Scirica, BM | 1 |
| Cooper, R | 1 |
| Brassard, J | 1 |
| McCabe, CH | 2 |
| Charlesworth, A | 2 |
| Skene, AM | 1 |
| Braunwald, E | 2 |
| Creagan, ET | 1 |
| Schutt, AJ | 1 |
| Ingle, JN | 1 |
| O'Fallon, JR | 1 |
| Wilcox, RG | 1 |
| Langer, A | 1 |
| Caspi, A | 1 |
| Berink, P | 1 |
| Lopez-Sendon, J | 1 |
| Toman, J | 1 |
| Anders, RJ | 1 |
| Alexander, JC | 1 |
| Skene, A | 1 |
| Sabatine, MS | 1 |
| Jang, IK | 1 |
| Wang, Z | 1 |
| Shi, J | 1 |
| Han, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer[NCT03943966] | 73 participants (Actual) | Interventional | 2019-11-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for alanine and Thrombopenia
| Article | Year |
|---|---|
Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Autoimmunity; Benzamidines; Humans; Immunoglobulin Fab F | 2002 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; A | 2000 |
3 trials available for alanine and Thrombopenia
| Article | Year |
|---|---|
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
Topics: Acute Disease; Alanine; Autoantibodies; Autoimmunity; Benzamidines; Female; Humans; Male; Middle Age | 2002 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
4 other studies available for alanine and Thrombopenia
| Article | Year |
|---|---|
COVID-19 and remdesivir in pediatric patients: the invisible part of the iceberg.
Topics: Adenosine Monophosphate; Alanine; Child; COVID-19 Drug Treatment; Humans; Respiratory Insufficiency; | 2021 |
Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454.
Topics: Administration, Oral; Alanine; Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Drug Evaluation, Pr | 2003 |
Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.
Topics: Alanine; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Leukope | 1983 |
[A novel point mutation in the transmembrane domain of platelet glycoprotein IX gene identified in a Bernard-Soulier syndrome patient].
Topics: Adult; Alanine; Bernard-Soulier Syndrome; Cell Size; Female; Humans; Membrane Proteins; Platelet Agg | 2001 |